Literature DB >> 971712

Theoretical analysis of the binding of salicylate by human serum albumin: the relationship between free and bound drug and therapeutic levels.

W D Wosilait.   

Abstract

The binding of salicylates by human serum albumin was analyzed by use of a computer program using previously published association constants and binding capacities for the two sets of binding sites on the protein. The analysis consisted of computing free and bound salicylates for a range of therapeutic and toxic concentration from 181 to 7246 mumole/L (25 to 1000 mg/L). At low and therapeutic levels the total amount of bound drug would exceed the amount of free drug. At higher levels, which included therapeutic and toxic ranges, the amount of free drug plasma, up to 2000 mumole/L the high affinity sites (Site 1), would bind most of the drug, but as the concentration of drug increased this site would approach saturation and the low affinity Site 2 would bind increasing amounts of salicylate. At high salicylate levels the amount of drug bound by the low affinity sites. Computation also showed that when the total amount of protein in the analysis was reduced, from 5, 4, 3, to 2 gm%, as in hypoalbuminemia, the total amount of drug bound by the protein would decrease and the quantity of free drug would increase. The amount of drug bound by each of the two sets of sites also fell as the concentration of protein decreased. Some of the possible clinical implications of these findings are discussed.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 971712     DOI: 10.1007/BF00561662

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  11 in total

1.  Computation of unbound anticoagulant values in plasma.

Authors:  W D Wosilait; S Garten
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1972-03

2.  Diphenylhydantoin side effects and serum albumin levels.

Authors: 
Journal:  Clin Pharmacol Ther       Date:  1973 Jul-Aug       Impact factor: 6.875

3.  Effect of temperature on the binding of salicylate by human serum albumin.

Authors:  J F Zaroslinski; S Keresztes-Nagy; R F Mais; Y T Oester
Journal:  Biochem Pharmacol       Date:  1974-06-15       Impact factor: 5.858

4.  A theoretical analysis of the binding of bilirubin by human serum albumin: the contribution of the two binding sites.

Authors:  W D Wosilait
Journal:  Life Sci       Date:  1974-06-01       Impact factor: 5.037

5.  Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Normal laboratory values.

Authors: 
Journal:  N Engl J Med       Date:  1974-01-03       Impact factor: 91.245

6.  Clinical toxicity of chlordiazepoxide and diazepam in relation to serum albumin concentration: a report from the Boston Collaborative Drug Surveillance Program.

Authors:  D J Greenblatt; J Koch-Weser
Journal:  Eur J Clin Pharmacol       Date:  1974-07-26       Impact factor: 2.953

7.  The relationship between the dose of warfarin, free drug in plasma, and its elimination in the bile of rats.

Authors:  W D Wosilait
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1973-11

8.  A method for computing active drug from plasma levels in cases of multiple binding.

Authors:  S Garten; W D Wosilait
Journal:  Comput Programs Biomed       Date:  1971-12

9.  Reciprocal relation between plasma albumin level and hepatic sulfobromophthalein removal.

Authors:  H Grausz; R Schmid
Journal:  N Engl J Med       Date:  1971-06-24       Impact factor: 91.245

10.  Salicylate intoxication. Significance of measurements of salicylate in blood in cases of acute ingestion.

Authors:  A K DONE
Journal:  Pediatrics       Date:  1960-11       Impact factor: 7.124

View more
  13 in total

1.  Salicylate protein binding in serum from young and elderly subjects as measured by diafiltration.

Authors:  L J Lesko; P K Narang; L Yeager; N R Cutler
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

2.  High unbound fraction of salicylate in plasma during intoxication.

Authors:  G Alván; U Bergman; L L Gustafsson
Journal:  Br J Clin Pharmacol       Date:  1981-06       Impact factor: 4.335

3.  The effects of a salicylate, ibuprofen, and naproxen on the disposition of methotrexate in patients with rheumatoid arthritis.

Authors:  T S Tracy; K Krohn; D R Jones; J D Bradley; S D Hall; D C Brater
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

4.  Plasma protein binding of dipyrone metabolites in man.

Authors:  E Zylber-Katz; L Granit; M Levy
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

5.  Model representation of salicylate pharmacokinetics using unbound plasma salicylate concentrations and metabolite urinary excretion rates following a single oral dose.

Authors:  J Shen; S Wanwimolruk; R D Purves; E G McQueen; M S Roberts
Journal:  J Pharmacokinet Biopharm       Date:  1991-10

6.  Monitoring plasma concentrations of salicylate.

Authors:  M Mandelli; G Tognoni
Journal:  Clin Pharmacokinet       Date:  1980 Sep-Oct       Impact factor: 6.447

7.  Effects of salicylate on HCO-3/Cl- exchange across the human erythrocyte membrane.

Authors:  E D Crandall; H I Winter; J D Schaeffer; A Bidani
Journal:  J Membr Biol       Date:  1982       Impact factor: 1.843

8.  Salicyl phenolic glucuronide pharmacokinetics in patients with rheumatoid arthritis.

Authors:  F Bochner; G G Graham; A Polverino; D M Imhoff; R A Tregenza; P E Rolan; L G Cleland
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

9.  Characterization of salicylate binding to synovial fluid and plasma protein in patients with rheumatoid arthritis.

Authors:  Z Trnavská; K Trnavský
Journal:  Eur J Clin Pharmacol       Date:  1980-11       Impact factor: 2.953

10.  Decrease of in vitro serum protein binding of salicylate in rheumatoid arthritis.

Authors:  P Netter; C Monot; M C Stalars; J M Mur; R J Royer; G Faure; J Pourel; J Martin; A Gaucher
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1984 Apr-Jun       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.